Intracranial response to capmatinib after progression on crizotinib in a patient with MET exon 14 skipping non-small cell lung cancer-a case report.
Balázs JóriOtto BundschuhMarkus FalkLukas C HeukampAlexander KlugeMarkus TiemannKay C WillbornJohannes WoitzikFrank GriesingerPublished in: Translational lung cancer research (2024)
-TKI like capmatinib with a better CNS penetration, it appears to be a promising approach for CNS metastasized NSCLC patients with METex14 mutations that failed on crizotinib. Further research is needed to more effectively understand and monitor resistance mechanisms using advanced diagnostic techniques such as DNA-based hybrid-capture (HC) next generation sequencing (NGS) to guide molecularly stratified therapy beyond the first line setting.
Keyphrases
- advanced non small cell lung cancer
- circulating tumor
- epidermal growth factor receptor
- tyrosine kinase
- blood brain barrier
- cell free
- case report
- single molecule
- copy number
- small cell lung cancer
- circulating tumor cells
- stem cells
- optic nerve
- gene expression
- bone marrow
- cell therapy
- nucleic acid
- smoking cessation
- replacement therapy
- chronic myeloid leukemia